Amrion Bioenergy Nutrients catalog supplement sales total $38.6 mil. in 1996.
This article was originally published in The Tan Sheet
Executive Summary
AMRION BIOENERGY NUTRIENTS CATALOG SALES TOTAL $38.6 MIL. for 1996, based on preliminary results released Feb. 5 that show consolidated sales for the Denver-based dietary supplement firm of approximately $54 mil. Corporate sales were up approximately 40% for the year, with the expectation of commensurate gains in earnings per share.
|
AMRION BIOENERGY NUTRIENTS CATALOG SALES TOTAL $38.6 MIL. for 1996, based on preliminary results released Feb. 5 that show consolidated sales for the Denver-based dietary supplement firm of approximately $54 mil. Corporate sales were up approximately 40% for the year, with the expectation of commensurate gains in earnings per share. Bioenergy Nutrients, a premium line of supplements, contains about 200 items. Amrion's other divisions are HealthSmart, Biodynamics, Physiologics, Cevan and Natrix International. Sales for HealthSmart, a value-priced catalog line, net after returns and allowances, totaled $8.1 mil. for the year, the company said during a teleconference on its preliminary financial results. Biodynamics, which sells in health food stores, generated revenues of roughly $1.8 mil. Physiologics, sold through health care professionals such as naturopaths and chiropractors, had sales of $1.7 mil. Cevan, the company's international division, had revenues in 1996 of $2.7 mil., and Natrix nutritionals, available in chains, recorded revenues of $1.4 mil., the company said. The company held "exhaustive...sometimes disruptive talks" in an attempt to forge such a connection, Crossen said, but proposals proved "not in the best interests" of the firm. Basically, Crossen said, Amrion has "found it too easy to duplicate product lines" so has no need for an acquisition or merger. The company can "knock out" a new product or line "in three months" and get it on the market, so a new partner is unnecessary, he noted. Amrion was in "some really interesting talks" though, he acknowledged. Amrion CEO Mark Crossen told the teleconference that the firm has 55 new products in its pipeline. The company's manufacturing facility has two-and-one-half shifts working daily on the encapsulation and bottling lines to keep up with demand, he noted, adding that Amrion hopes to double its capacity for growth in 1997-98. The company is looking to move to a new leased manufacturing and headquarters facility within 14-16 months. Amrion's search for a potential buyer or business combination, announced in mid-October, has been terminated, Crossen noted ("The Tan Sheet" Oct. 21. p. 13). |